WST
WEST PHARMACEUTICAL SERVICES INC
NYSE · Healthcare · Medical - Instruments & Supplies · US
$409.07
+0.51%Oct 29, 2026, 12:11 UTC
WEST PHARMACEUTICAL SERVICES INC reported quarterly earnings of $2.66 per share, above the Zacks Investment Research, Inc. Consensus Estimate of $2.18 and compared with $1.96 per share a year earlier.
Source:Oct 29, 2026, 11:47 UTC
West Pharmaceutical Services repurchased $231 million of its shares during the third quarter of 2026.
Oct 29, 2026, 10:00 UTC
WEST PHARMACEUTICAL SERVICES INC raised its full-year 2026 net sales and adjusted diluted EPS guidance.
Source:Oct 29, 2026, 10:00 UTC
WEST PHARMACEUTICAL SERVICES INC reported third-quarter 2026 financial results.
Source:Oct 28, 2026, 07:11 UTC
West Pharmaceutical Services entered into a new five-year credit agreement providing a $750 million revolving facility and a $200 million term loan, for an initial aggregate principal amount of $950 million.
Oct 28, 2026, 07:11 UTC
West Pharmaceutical Services prepaid $130 million outstanding under its existing credit agreement with Bank of America and terminated the agreement without an early termination penalty.
Oct 19, 2026, 22:04 UTC
West Pharmaceutical Services declared a fourth-quarter dividend of $0.26 per common share, an 18% increase from the prior quarter.
Source:Oct 8, 2026, 10:00 UTC
West Pharmaceutical Services announced that it will release its third-quarter 2026 financial results before the market opens on October 29, 2026, and hold a conference call at 8:00 a.m. Eastern Time.
Source:Aug 22, 2026, 07:05 UTC
Advisors Capital Management LLC acquired a new stake in West Pharmaceutical Services, Inc. during the second quarter, buying 4,270 shares valued at approximately $1,533,000.
Source:Jul 23, 2026, 10:00 UTC
West Pharmaceutical Services reported its financial results for the second quarter of 2026.
Jul 21, 2026, 20:00 UTC
West Pharmaceutical Services declared a regular quarterly dividend of $0.22 per share.
Source:Jul 9, 2026, 14:01 UTC
West Pharmaceutical Services completed the sale of its SmartDose 3.5mL platform to AbbVie.
Source:Jul 1, 2026, 20:30 UTC
West Pharmaceutical Services completed the sale and transfer of the manufacturing and supply rights for SmartDose 3.5mL On-Body Delivery System and associated facilities.
Source:Jun 2, 2026, 05:53 UTC
West Pharmaceutical Services announced that Michel Lagarde will succeed Eric Green as President and CEO, effective August 31, 2026, and Robert F. Friel will become Board Chair.
Source: